InSyBio
InSyBio is a private biotechnology company offering an AI/ML-powered SaaS platform for multi-omics biomarker discovery and predictive analytics, serving pharmaceutical R&D, academic researchers, the nutrition and cosmetics industry, and healthcare providers across the UK, Greece, and USA.
- Company typePrivate
- Founded2013
- HeadquartersNarragansett, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What InSyBio does
InSyBio is a private biotechnology company founded in 2013 that develops an AI/ML-powered software-as-a-service platform, InSyBio Suite, for multi-omics biomarker discovery and predictive analytics applied to precision medicine and nutrition. The platform integrates genomics, transcriptomics, proteomics, and metabolomics data through proprietary algorithms — including a multi-objective evolutionary optimization method and Adaptive Boosting for class imbalance — packaged as modular tools (BioNets, Interact, Datastore, ncRNASeq, Pipelines, DNASeq, Biomarkers) accessible via web browser without bioinformatics expertise. The company generates revenue through SaaS subscriptions to InSyBio Suite, fixed-price micro-analysis services, a "Pay Upon Success" BioData Analysis Services offering, and professional bioinformatics services, with customers spanning pharmaceutical R&D, academic research institutes, the nutrition and cosmetics industry, and healthcare providers. Beyond the research SaaS, InSyBio has expanded into clinical decision support with a Diagnostics product line that includes PrecisionCHF (75% AUC for 5-year mortality in CHF), PrecisionHCM (97% AUC for short-term outcomes), Precision Chronic Pain Treatment Tools (>82% accuracy across 600+ patients), and Metabolic AI (co-developed with Fitly Health for metabolic syndrome, prediabetes, and Type 2 diabetes). The company operates as InSyBio Group with three legal entities across the UK, Greece, and USA, is supported by five active EU Horizon Europe and MSCA research projects, and has reported working with hundreds of academic and enterprise clients since 2013. The most recent commercial activity includes a 2023 Series A round targeting €2,000,000 led by Loyal VC, a 2023 CPHI Pharma Award for Best Start-Up Initiative in Pharma, and a 2026 selection for Pfizer's Center for Digital Innovation Start4Health ScaleUps Studio programme.
InSyBio firmographics
Firmographics- Name
- InSyBio
- Legal name
- InSyBio Group
- Website
- https://insybio.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- InSyBio is a private biotechnology company offering an AI/ML-powered SaaS platform for multi-omics biomarker discovery and predictive analytics, serving pharmaceutical R&D, academic researchers, the nutrition and cosmetics industry, and healthcare providers across the UK, Greece, and USA.
- Ownership category
- akta.pro rank
InSyBio industry classification
Industry- Product category
- Bioinformatics Software for Precision Medicine and Nutrition
- NAICS
- Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where InSyBio is headquartered
LocationHeadquarters
- HQ city
- Narragansett
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
InSyBio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Software-as-a-Service Subscriptions: SaaS platform subscriptions to InSyBio Suite with tiered pricing plans. Users can purchase short-term access passes or fixed-price micro-analysis services. Revenue is generated through recurring subscription fees with annual and monthly billing options. The company also offers a free one-month trial to drive conversion to paid plans.
- Professional Bioinformatics Services: Bespoke bioinformatics and software services for academic research, pharma industry, and nutrition/cosmetics industry. Includes 'Pay Upon Success' BioData Analysis Services where fees are contingent on successful outcomes. Fixed-price micro-analysis services also offered.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free one-month trial license of InSyBio Suite |
| Subscription | Annual | InSyBio Suite Paid Subscription Tiers |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels9 records
InSyBio product offering
Product offeringCore offering
InSyBio develops and sells InSyBio Suite, a cloud-based SaaS platform that integrates multi-omics and clinical data for biomarker discovery and predictive analytics in precision medicine and nutrition. The platform is designed for non-bioinformatics experts and combines proprietary machine learning algorithms with specialized modules for protein interaction analysis, RNA/DNA sequencing, biological network reconstruction, and automated pipelines. InSyBio also offers standalone diagnostic tools (Precision Chronic Pain, PrecisionCHF, PrecisionHCM, Metabolic AI) and bespoke bioinformatics services on a pay-upon-success basis.
Product overview
InSyBio is a biotechnology company offering a unified software-as-a-service (SaaS) platform called InSyBio Suite for precision medicine and nutrition through biomarker discovery and predictive analytics. The platform comprises multiple specialized modules: InSyBio BioNets (biological network analysis for biomarker discovery), InSyBio Interact (protein-protein interaction analysis with 2M+ interaction database), InSyBio Datastore (biological data storage), InSyBio ncRNASeq (non-coding RNA and single-cell RNA sequencing analysis), InSyBio Pipelines (automated biomarker discovery workflows), InSyBio DNASeq (DNA sequencing analysis), and InSyBio Biomarkers (multi-omics predictive analytics using machine learning). The company also provides diagnostic tools including InSyBio Precision Chronic Pain Treatment Tools, PrecisionCHF, PrecisionHCM, and Metabolic AI (co-developed with Fitly Health), alongside open-source tools (Virtuous Multi-Taste, GENA, MEvA-X, Scaffold Design Optimization) developed through EU Horizon projects. Solutions are offered via subscription licensing (InSyBio Suite), free trials, and pay-upon-success service models.
Differentiator
Problem solved
Functional benefit
Brands
- InSyBio Suite: AI-powered SaaS platform for multi-omics data analysis, biomarker discovery, and predictive analytics in precision medicine and nutrition.
- InSyBio Diagnostics
- InSyBio Precision Chronic Pain Treatment Tools
- Metabolic AI
Products and services
- InSyBio Suite Cloud-based SaaS machine learning platform that comprehensively integrates multi-omics and clinical data for biomarker discovery and predictive analytics, designed for non-bioinformatics experts and unifying multiple specialized tools under one subscription.
- InSyBio Precision Chronic Pain Treatment Tools AI-powered diagnostic tools that stratify chronic pain patients and identify the best non-opioid treatment formulations (Topical Analgesics, Salonpas, Kailo, Upatras Osteoarthritis) based on demographics, clinical characteristics, and questionnaire responses. Co-developed with Clarity Science LLC using OPERA study data.
- PrecisionCHF Tool Outcome prediction and precision treatment tool for congestive heart failure patients. Predicts 5-year mortality with 75% AUC and recommends therapeutic protocol optimizations to reduce patient risk.
- PrecisionHCM Tool Outcome prediction and precision treatment tool for hypertrophic cardiomyopathy patients. Predicts short-term mortality (until discharge) with 97% AUC and recommends medication plan optimizations.
- Metabolic AI Precision nutrition program for metabolic syndrome, prediabetes, and Type 2 diabetes, co-developed with Fitly Health. Powered by gut microbiome analysis, predictive generative AI, precision nutrition tracking, and virtual coaching for personalized metabolic health management.
- Pay Upon Success BioData Analysis Services Bespoke bioinformatics and data analysis services offered on a contingency basis, where fees are contingent on successful outcomes. Includes fixed-price micro-analysis services and short-term access passes for specific analyses, targeting academic research, pharma industry, and nutrition/cosmetics customers.
- InSyBio Personalization Test Service for building personalized tests faster, more accurately, and using low sample size studies, supporting precision medicine applications.
- InSyBio Cosmetics Domain-specific biomarker discovery and analysis tools tailored for the cosmetics industry, supporting efficacy testing and personalization for nutrition and cosmetics sector customers.
- Virtuous Multi-Taste Predictor Multi-class predictor for taste sensations (sweet, umami, bitter, other) based on a multi-objective machine learning method. Predicts taste of chemical compounds based on their physiochemical properties. Developed within the VIRTUOUS Horizon 2020 project.
- Scaffold Design Optimization and Prediction Tool Tool combining genetic algorithms with machine learning models to support scaffold design optimization and prediction for biomedical and materials engineering applications. Compatible with multiple bioreactor designs via universal scaffold design parameters. Developed within the OSTEONET Horizon Europe project.
- Experimental Design Optimization and Prediction Tool Tool integrating genetic algorithms with machine learning models to optimize and predict bioreactor configurations for enhanced cell vitality and production. Operated with datasets from two different bioreactors and static control environments (139 samples total). Developed within the REGENERATION Horizon Europe project.
Quantifiable outcome
- At least 10% increase in predictive accuracy for biomarker discovery tasks compared to traditional approaches
- +5 more outcomes
Companies that use InSyBio
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
InSyBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability9 records
Feature12 records
InSyBio partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- Pfizer Center for Digital Innovation (CDI)coreSelected for the Start4Health ScaleUps Studio Programme led by Pfizer CDI. Participation includes preparation workshops with Found.ation, introductory sessions with Pfizer's Embedded Innovation team, and a Solution Exploration Workshop with Pfizer business units. The track is designed for mature startups to co-design potential collaboration projects with Pfizer. Scheduled February-March 2026.
- Patras Science ParkminorInSyBio accepted into the A4SUSTINNO accelerator programme organized by Patras Science Park in collaboration with Point of Synergy. The programme offers at least 40 hours of educational content, 4 hours of personalized support per company, and 2 presentation events. Supports digital technology startups in Greece's innovation ecosystem.
- Syndesis HealthcoreStrategic partnership to leverage clinical and genomic data on Syntium, Syndesis' data platform of global healthcare data, to accelerate R&D in cardiovascular health, oncology, and rare diseases. The partnership enabled co-development of PrecisionCHF and PrecisionHCM AI tools using Syntium's curated clinical datasets. The collaboration demonstrated the value of combining curated clinical data with AI-driven biomarker discovery technology.
- Fitly HealthcorePartnership to create the world's first Metabolic AI precision nutrition program for metabolic syndrome, prediabetes, and Type 2 diabetes. InSyBio provides gut microbiome analysis and predictive analytics; Fitly Health provides SmartPlate technology, virtual coaching, and precision nutrition tracking. The program includes financial incentives for patient adherence over a 12-month period.
- GALATEA Horizon Europe Project ConsortiumcoreGALATEA Horizon Europe Project focused on advancing innovation in digital health through AI-driven digital twin technologies for personalised infant nutrition. InSyBio participated in midterm meeting in Athens (March 2026) at Athena Research Center. Consortium brings together expertise from multiple disciplines across Europe.
- OSTEONET Project Consortium (EU Horizon Europe MSCA)coreHorizon Europe MSCA Staff Exchange project (grant agreement No. 101086329) developing reliable and sustainable 3D in vitro models of healthy and aged bone tissue for preclinical drug screening. Consortium includes academic and industry partners across Europe. Led to bioreactor characterization and tissue engineering publications.
- REGENERATION Project Consortium (EU Horizon Europe MSCA)coreHorizon Europe MSCA Staff Exchange project (grant agreement No. 101131255) focused on PeRsonalised treatmEnts and pain manaGEmeNt for rEpaiR of Aged bone Tissue with Quantum Molecular Resonance (QMR). Partners include Dalle Molle Institute for AI, National Research Council, Cellex S.R.L., and Athena Research Center. Led to bone regeneration computational methods publication.
- Clarity Science LLCcoreCollaboration to develop machine learning-based tools for predicting chronic pain patient response to non-opioid topical analgesic treatments. The OPERA study (Optimizing Patient Experience and Response to Topical Analgesics) provided clinical data. Developed tools for Topical Analgesics, Salonpas, Kailo, and Upatras Osteoarthritis formulations.
- JSS Medical Research Inc.minorStrategic partnership to pioneer precision medicine innovation in clinical trials. Axios Investments Corporation facilitated the partnership. Aims to transform the clinical trial process through biomarker discovery and patient stratification.
- VIRTUOUS Project Consortium (EU Horizon 2020 RISE)coreMarie Skłodowska-Curie Research and Innovation Staff Exchange project to develop a virtual tongue for taste prediction. Partners include Politecnico di Torino (Italy), Dalle Molle Institute for Artificial Intelligence (Switzerland), Industrial Systems Institute (Greece), and 4 other European consortium members. Led to Virtuous Multi-Taste predictor and Taste Receptor interactome publications.
- International AcceleratorminorInSyBio joined the International Accelerator program in Austin, Texas to access the US biotechnology market. Participated in Demo Day in October 2019 showcasing breakthrough technology to the Texas investment community.
Scale indicators12 records
Recent moves6 records
Expansion highlights7 records
InSyBio competitors and assessment
Company assessmentEmerging players
- Benchling: Cloud platform for life sciences R&D including molecular biology, multi-omics, and lab informatics. Targets the same biotech/pharma R&D audience as InSyBio with a broader lab-notebook-to-analytics stack, but is more focused on experimental workflows than biomarker discovery.
- GNS Healthcare: AI-driven precision medicine company applying causal machine learning to multi-omics and clinical data for pharma R&D. Closely comparable to InSyBio Biomarkers in using ML on omics data for outcome prediction, with a more focused oncology/PARP inhibitor track record.
- BC Platforms: Genomics and real-world data platform for pharma R&D and precision medicine, with strong European footprint similar to InSyBio's. Offers comparable genomic data management and analysis tooling for biomarker discovery and clinical research.
- Strand Life Sciences: Provides bioinformatics software and clinical genomics interpretation services for research and diagnostics. Overlaps with InSyBio in multi-omics analytics and clinical variant interpretation, with meaningful presence in India and emerging markets.
Broad incumbents
- QIAGEN Digital Insights: Division of QIAGEN offering industry-standard bioinformatics tools (Ingenuity Pathway Analysis, QIAseq) for omics interpretation and biomarker discovery. Provides overlapping capabilities to InSyBio's suite but as part of QIAGEN's broader sample-prep-to-interpretation portfolio for pharma and academic customers.
- Illumina (DRAGEN / BaseSpace): Dominant sequencing platform vendor that has expanded into bioinformatics via DRAGEN and BaseSpace Sequence Hub. Overlaps with InSyBio's DNA-seq and multi-omics analysis capabilities, but as a broader sequencing-instruments-and-software incumbent rather than a focused SaaS play.
Regional players
- Fabric Genomics (formerly Omicia): AI-based clinical genomic interpretation platform for hereditary disease and oncology. Comparable to InSyBio Diagnostics' clinical decision support positioning, with primary commercial footprint in North America rather than EU/US dual presence.
Direct peers
- DNAnexus: Cloud-based bioinformatics platform for genomics and multi-omics data analysis, serving pharma R&D, clinical research, and diagnostic labs. Closely matches InSyBio's positioning as a SaaS environment for biomarker discovery and omics pipelines.
- Velsera (formerly PierianDx / Seven Bridges): Clinical genomics and multi-omics informatics platform supporting diagnostic interpretation and pharma research workflows. Directly comparable to InSyBio Diagnostics and InSyBio Suite as an integrated environment for variant interpretation, biomarker discovery, and clinical decision support.
- SOPHiA GENETICS: AI-driven genomics and multi-omics clinical analysis platform serving hospitals, pharma, and research centers — directly comparable to InSyBio in offering SaaS-based biomarker discovery and clinical decision support across multi-omics data, with a more mature enterprise footprint and listed on Nasdaq.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
InSyBio social profiles
Digital presenceInSyBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
InSyBio leadership team
Management profileNumber of profiles
Profiles8 records
InSyBio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InSyBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InSyBio
What does InSyBio do?
InSyBio develops and sells InSyBio Suite, a cloud-based SaaS platform that integrates multi-omics and clinical data for biomarker discovery and predictive analytics in precision medicine and nutrition. The platform is designed for non-bioinformatics experts and combines proprietary machine learning algorithms with specialized modules for protein interaction analysis, RNA/DNA sequencing, biological network reconstruction, and automated pipelines. InSyBio also offers standalone diagnostic tools (Precision Chronic Pain, PrecisionCHF, PrecisionHCM, Metabolic AI) and bespoke bioinformatics services on a pay-upon-success basis.
Is InSyBio a public or private company?
InSyBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was InSyBio founded?
InSyBio was founded in 2013. It employs 11 to 50 people.
Where is InSyBio based?
InSyBio is headquartered in Narragansett, United States, in the North America region.
How does InSyBio make money?
Two revenue lines are on record. Software-as-a-Service Subscriptions are the primary driver. The others are professional Bioinformatics Services.
Who are InSyBio's main competitors?
Emerging players on record are Benchling, GNS Healthcare, BC Platforms and Strand Life Sciences. Broad incumbents are QIAGEN Digital Insights and Illumina (DRAGEN / BaseSpace). Fabric Genomics (formerly Omicia) is listed as a regional player. Direct peers are DNAnexus, Velsera (formerly PierianDx / Seven Bridges) and SOPHiA GENETICS.
Does InSyBio have an API?
No public API is recorded for InSyBio.
What industry is InSyBio in?
InSyBio's product category is Bioinformatics Software for Precision Medicine and Nutrition. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 5132 and its SIC code is 7372.